Connect with us

News

Can Eli Lilly become the first $1tn drugmaker?

Published

on

Can Eli Lilly become the first tn drugmaker?

Times are good at Eli Lilly. Wall Street’s insatiable appetite for weight-loss drug stocks looks set to turn the company into the world’s first $1tn drugmaker by market value.

But war stories about gloomier times are never far away when you run a pharmaceutical company. In the late 2000s, Eli Lilly’s share price neared all-time lows as patents of its blockbuster psychiatric drugs — chief among them Prozac, Zyprexa and Cymbalta — expired.

Consolidation was then sweeping the industry, recalls chief executive Dave Ricks, a 25-year veteran, and Eli Lilly was at risk of becoming “the back end of a hyphen to someone else”. The wheel of fortune has since turned. The company’s main problem is building production lines fast enough to meet demand for its blockbuster diabetes and weight-loss drugs Mounjaro and Zepbound, part of a new class of drugs known as GLP-1s.

The drugmaker has invested $20bn in manufacturing facilities over the past four years, and on Wednesday said it was spending a further $4.5bn on building a production facility for drugs in clinical trial in its home state of Indiana. The pool of possible patients is one of the largest of any drug in history: there are more than 100mn US adults with obesity and 1bn people worldwide.

“Everyone has a biomarker in their bathroom, it’s called a scale,” says Ricks, speaking from a production facility under construction on the site of Eli Lilly’s Indianapolis headquarters. “So many people get a benefit, and they get it pretty quickly, and so then there’s a consumer interest cycle that is pretty powerful.”

Advertisement

Some content could not load. Check your internet connection or browser settings.

With the most potent weight-loss shot and a pipeline of 11 experimental treatments, including what is widely expected to be the first approved small molecule GLP-1 pill, Eli Lilly stands to be the biggest winner in a market that is projected to grow to $130bn a year in peak sales by the end of the decade.

But Ricks is far from complacent. He spends much of his time working to boost manufacturing capacity to outcompete rival Novo Nordisk. Meanwhile, Eli Lilly is fighting off competition from copycat weight-loss drugs and other drug developers entering the lucrative field, and coming under increasing pressure from politicians and patients over the price of its treatments.

Investors are also becoming wary over the company’s frothy valuation, which stood at $842bn as of market close on Monday, or 54-fold higher than projected earnings over the next 12 months, a height never reached before in the industry.

“Everybody is jumping blindly on [Eli] Lilly and all these stocks so they will keep grinding up but they are priced for perfection,” says one top-10 shareholder. “If investors get scared about the 10 other players with weight-loss drugs and the prospect of pricing pressure, they could be in trouble.”

Advertisement
Daniel Skovronsky
Daniel Skovronsky, Eli Lilly’s chief scientific officer, says the company’s long-term mission is not only to boost its success, but also to avoid pharma’s ‘boom and bust’ cycle © AJ Mast/FT
A manufacturing facility filled with stainless steel equipment and interconnected pipes
An Eli Lilly GLP-1 manufacturing facility in Indianapolis that is set to start producing this year. Its rival Novo Nordisk shook up the market with the launch of the GLP-1 drug Ozempic in 2017 © AJ Mast/FT

But the company hopes to consolidate its position among the top 10 most valuable companies in the US by staying ahead of the competition. For Eli Lilly, this will mean pouring its extraordinary revenues into research and development to prepare for when its weight-loss drugs reach the so-called patent cliff when generic competition arrives, sometime in the mid-2030s.

The tech stocks that compete for the title of most valuable company — the likes of Microsoft, Apple, Nvidia and Google — share a “stickiness with their customers . . . that the pharmaceutical industry in the past has lacked”, says Daniel Skovronsky, Eli Lilly’s chief scientific officer.

The long-term mission for the company is not just to rise to greater heights but to avoid a return to darker times by cultivating some of that consumer loyalty. “Our mission”, adds Skovronsky, “is to get out of that boom and bust cycle of pharma”.


In 2018, after Swiss drugmaker Roche turned down the rights to license a promising GLP-1 pill to treat type 2 diabetes from its sister company Chugai, a rivalry dating back more than a century boiled up once again.

Eli Lilly beat out its Danish competitor Novo Nordisk for the rights to the experimental drug after a short bidding war, paying just $50mn upfront, according to two people familiar with discussions. Novo Nordisk declined to comment.

Skovronsky could not recall whether the pill’s potential as a weight-loss treatment was even discussed at the time of the licensing deal.

Advertisement

But the pill — now known as orforglipron, which looks set to be first small molecule anti-obesity pill if it launches as planned in 2026 — is one of several fronts in which Eli Lilly appears to be outmanoeuvring Novo Nordisk for supremacy in the weight-loss drug market.

“For a century, we’ve competed with [Novo Nordisk] directly or indirectly,” says Ricks. “Competition is good for consumers in that way: it speeds up things because you race, you work harder, we can iterate in ways that produce better products . . . so there has been a sort of leapfrogging.”

Some content could not load. Check your internet connection or browser settings.

In 1923, Eli Lilly was first out of the blocks with a commercial insulin product to treat diabetes, which until then was considered a death sentence. Novo, then a standalone company before its merger with Nordisk, created a longer-lasting version and the first insulin pen.

In 1982, Eli Lilly launched the first synthetic, mass-producible version of human insulin. In 2005, Eli Lilly then created the first GLP-1 drug — a twice-daily injection, but Novo Nordisk would revolutionise the market with the launch of Ozempic in the US in 2017.

Despite Novo Nordisk being first to market, Eli Lilly has benefited from “a second mover advantage” with the launch of its weight-loss medicines, says Rajesh Kumar, head of healthcare equity research at HSBC. “They can see what traps the guy ahead of them is falling into,” he says, allowing them to ramp up manufacturing faster and to invest in next-generation products.

Advertisement

This year, Mounjaro and Zepbound, which are both based on the active ingredient tirzepatide, are set to generate $18.8bn in sales between them, according to analyst consensus estimates — edging closer to Novo Nordisk’s $27bn in projected revenues from Ozempic and Wegovy, despite being on sale for a shorter period of time. Sales from Eli Lilly’s GLP-1 franchise are projected to surpass Novo Nordisk’s by 2027.

Eli Lilly’s first laboratory building in 1876
Eli Lilly’s first laboratory building in 1876. The drugmaker’s early success included revolutionising diabetes treatment in the 1920s with the first commercial insulin product
The company’s present-day headquarters in Indianapolis
The company’s present-day headquarters in Indianapolis. Eli Lilly has invested billions in manufacturing facilities in recent years © AJ Mast/FT

If orforglipron launches on schedule in 2026, Eli Lilly would enjoy a two-year monopoly of the weight-loss pill market before rivals caught up. At the same time, the company is also developing retatrutide, a treatment that activates three different gut peptides and in mid-stage trials resulted in 24 per cent body mass reduction, far more dramatic than the effects of any existing treatment.

The company is also racing to prove the added benefits of tirzepatide for knock-on effects of obesity, such as sleep apnoea, cardiovascular risk and chronic kidney disease, helping to ease the path to wider insurance coverage. Medicare, the state-backed healthcare programme mostly for over-65s, only covers weight-loss drugs when a patient is suffering from another comorbidity.

“We’re going to eat the elephant one step at a time here . . . by proving the indications not just to lower weight but for the consequences of that,” says Ricks. “I think in five years we’ll look back and say mostly those diseases can be augmented by changing their weight . . . and the payers will look back and say, ‘Yeh, we should cover [tirzepatide] in all these conditions and the precursor condition which is medical obesity.’”

Beyond its longtime rival, Eli Lilly is also facing competition from other quarters. As many as 16 new obesity drugs could launch by the end of the decade, including from drugmakers AstraZeneca, Pfizer and Amgen, according to PitchBook.

But more imminently, Eli Lilly is fighting back against an array of copycat weight-loss drugs. The US Food and Drug Administration permits compounding pharmacies, which typically prepare customised medication, to reproduce trademarked drugs when there is a shortage, and these have flooded the market.

Advertisement

Ricks argues that there was “no rationality” for tirzepatide to remain on the FDA’s shortage list because of Eli Lilly’s efforts to ramp up supply, adding that compounding presented a risk to patients. “Let’s partner together to solve the production problem, let’s not use this trap door, which exposes Americans to adulterated products with unapproved [active pharmaceutical ingredients].”

With competitors at Eli Lilly’s heels and its key advantage being eroded, investors see warning signs that the company’s valuation may be nearing its peak.

A top-25 shareholder predicts that Eli Lilly will pass the $1tn milestone but says that is “close to the top”. “There’s the inevitable patent cliff, there’s competition and soon there’s going to be a price war to the bottom,” says the investor. “It seems like this is peak enthusiasm for [Eli Lilly].”


If Eli Lilly really wants to escape the pharmaceutical industry’s boom and bust cycle, its research and development team will have to get to work on discovering the next era-defining medicine. The task for Eli Lilly is to determine “what is your next giant pie-in-the-sky thing”, says one investor.

The company is hoping such opportunities may be hidden in the real-world data from the rollout of its anti-obesity medications.

Advertisement

Some content could not load. Check your internet connection or browser settings.

Early signs suggest that the hundreds of thousands of patients prescribed tirzepatide are starting to see other surprising effects from the treatment: a reduction in anxiety and depression symptoms as well as better control over compulsive behaviours such as smoking and drinking, according to Skovronsky.

Eli Lilly has already put the treatments to work against autoimmune diseases, such as psoriatic arthritis, in combination with other medicines, but Skovronsky says that the effects on mental health and addiction “are intriguing enough that we’re considering . . . how to attack the question of whether these drugs can help those kinds of diseases”.

The drugmaker is also considering including people who are not overweight, but are at risk of weight gain, in future trials of its weight-loss pills and other treatments, suggesting it is already searching for ways to expand the weight-loss drug market.

The biggest question for Eli Lilly, however, is what the company will do with the unprecedented windfall from its weight-loss drugs.

Eli Lilly chief executive David Ricks
Eli Lilly chief executive Ricks says he has favoured early-stage R&D bets over big, set-piece acquisitions © AJ Mast/FT
A lab setup with three transparent vessels containing yellow liquid
Manufacturing equipment at the drugmaker’s new lab in Kinsale, Ireland. Ricks says the company kept going with diabetes and obesity research when other pharma groups gave up © Paulo Nunes dos Santos/Bloomberg

Between now and 2030, analysts expect the business to generate $187bn in free cash flow, with which Eli Lilly can do whatever it wants. As one venture capitalist put it: while industry watchers are obsessing over Eli Lilly’s market value, what will be more defining is what Lilly does “once the money comes in the door”.

“Our capacity to spend is going up so we should look at everything but probably not change our principles,” says Ricks, adding that he favoured early-stage R&D bets over big, set-piece acquisitions that provide a bump in revenues but curtail growth.

Advertisement

“When this company’s future was in doubt . . . we made a bet on R&D and we survived that by being inventive,” says Ricks, pointing to how the company persisted with diabetes and obesity research when other pharma groups gave up.

“That’s probably the way we maintain momentum by being inventive,” says Ricks. “We deploy dollars by project, not by some top-down math . . . so that requires us to get into the weeds on each project and get excited about it or not.”

When Merck’s blockbuster cancer immunotherapy drug Keytruda launched in 2014, Skovronsky recalls rushing to catch up and launch Eli Lilly’s own version of the class of drugs known as checkpoint inhibitors. He predicts that many rival drugmakers will miss the next wave of innovation as they try to find a route into the obesity market.

Meanwhile, Eli Lilly will have the breathing room to pursue its next big innovation: now that Kisunla, its treatment for people with early-stage Alzheimer’s, has been approved in the US, it is putting the medicine to work as preventive treatment for the incurable brain disorder.

Skovronsky adds that Eli Lilly, whose previous biggest drug was depression treatment Prozac, is likely to push back into psychiatry. Non-opioid painkillers are also an area of potential growth, as the US continues to search for solutions to the opioid crisis.

Advertisement

Companies “have gotten challenged by investors in the years coming up to the cliff not because the rest of the business isn’t growing through the cliff but because the rest of the business just is uninteresting”, says Jacob Van Naarden, who runs Eli Lilly’s oncology division.

For Eli Lilly, the challenge will be to prove to investors that the rest of its business can be as attractive as its blockbuster GLP-1 drugs. “If you remove the diabetes and obesity businesses, they don’t execute that well,” says one investor. “There’s some risk in just going into new areas, because just like Novo actually they’re really good at this one thing . . . the rest are a mixed bag.”

And the odds are long. Discovering hugely popular medicines like statin Lipitor, autoimmune medicine Humira, Keytruda and now the GLP-1s “happens pretty infrequently and usually not by the same company twice in a row”, says Van Naarden. “Maybe it’s us — that’d be great.”

Data visualisation by Ian Bott, Keith Fray and Patrick Mathurin

Advertisement

News

Who is Delcy Rodríguez, Venezuela’s leader after Maduro’s capture? | CNN

Published

on

Who is Delcy Rodríguez, Venezuela’s leader after Maduro’s capture? | CNN

Following the capture of President Nicolás Maduro during a US military operation in Venezuela, the command of the South American country has fallen into the hands of Executive Vice President Delcy Rodríguez.

That is what Venezuela’s constitution outlines in its different scenarios anticipating a president’s absence. Under Articles 233 and 234, whether the absence is temporary or absolute, the vice president takes over the presidential duties.

Rodríguez – also minister for both finance and oil – stepped into the role on Saturday afternoon. Hours after the capture of Maduro and his wife, Cilia Flores, she chaired a National Defense Council session, surrounded by other ministers and senior officials, and demanded the couple’s “immediate release” while condemning the US military operation.

Standing before the Venezuelan flag, Rodríguez said the early-morning operation represents a blatant violation of international law and Venezuela’s sovereignty. She added that the action must be rejected by Venezuelans and condemned by governments across Latin America.

“We call on the peoples of the great homeland to remain united, because what was done to Venezuela can be done to anyone. That brutal use of force to bend the will of the people can be carried out against any country,” she told the council in an address broadcast by state television channel VTV.

Advertisement

Rodríguez, 56, is from Caracas and studied law at the Central University of Venezuela.

She has spent more than two decades as one of the leading figures of chavismo, the political movement founded by President Hugo Chávez and led by Maduro since Chávez’s death in 2013.

Alongside her brother Jorge Rodríguez, the current president of the National Assembly, she has held various positions of power since the Chávez era. She served as minister of communication and information from 2013 to 2014 and later became foreign minister from 2014 to 2017. In that role, she defended Maduro’s government against international criticism, including allegations of democratic backsliding and human rights abuses in the country.

As foreign minister, Rodríguez represented Venezuela at forums such as the United Nations, where she accused other governments of seeking to undermine her country.

In 2017, Rodríguez became president of the Constituent National Assembly that expanded the government’s powers after the opposition won the 2015 legislative elections. In 2018, Maduro appointed her vice president for his second term. She retained the post during his third presidential term, which began on January 10, 2025, following the controversial July 28, 2024, elections. Until the president’s capture, she served as Venezuela’s chief economic authority and minister of petroleum.

Advertisement

Venezuela’s opposition maintains that the 2024 elections were fraudulent and that Maduro is not a legitimately elected president. They insist that the true winner was former ambassador Edmundo González Urrutia, a position supported by some governments in the region.

José Manuel Romano, a constitutional lawyer and political analyst, told CNN that the positions Rodríguez has held show she is a “very prominent” figure within the Venezuelan government and someone who enjoys the president’s “full trust.”

“The executive vice president of the republic is a highly effective operator, a woman with strong leadership skills for managing teams,” Romano said.

“She is very results-oriented and has significant influence over the entire government apparatus, including the Ministry of Defense. That is very important to note in the current circumstances,” he added.

On the path to an understanding with the US?

Hours after Maduro’s capture, and before Rodríguez addressed the National Defense Council, US President Donald Trump said at a press conference that Secretary of State Marco Rubio had spoken with the vice president. According to Trump, she appeared willing to work with Washington on a new phase for Venezuela.

Advertisement

“She had a conversation with Marco. She said, ‘We’re going to do whatever you need.’ I think she was quite courteous. We’re going to do this right,” Trump said.

Trump’s remarks, however, surprised some analysts, who believe Rodríguez is unlikely to make concessions to the United States.

“She is not a moderate alternative to Maduro. She has been one of the most powerful and hard-line figures in the entire system,” Imdat Oner, a policy analyst at the Jack D. Gordon Institute and a former Turkish diplomat based in Venezuela, told CNN.

“Her rise to power appears to be the result of some kind of understanding between the United States and key actors preparing for a post-Maduro scenario. In that context, she would essentially serve as a caretaker until a democratically elected leader takes office,” the analyst added.

In her first messages following Maduro’s capture, Rodríguez showed no signs of backing down and, without referencing Trump’s statements, closed the door to any potential cooperation with the United States.

Advertisement

Earlier in the morning, during a phone interview with VTV, Rodríguez said the whereabouts of Maduro and Flores were unknown and demanded proof that they were alive. Later in the afternoon, during the National Defense Council session, she escalated her rhetoric, condemned the US operation and, despite the circumstances, insisted that Maduro remains in charge of Venezuela.

“There is only one president in this country, and his name is Nicolás Maduro Moros,” said Rodríguez — now, by force of events, the most visible face of the government.

Reuters news agency contributed to this report.

Advertisement
Continue Reading

News

For those who help the poor, 2025 goes down as a year of chaos

Published

on

For those who help the poor, 2025 goes down as a year of chaos

Paul B. Miller shops at The Market food pantry in Logan, Ohio on Dec. 9. Food aid was just one of many services offered here that faced disruption in 2025.

Rich-Joseph Facun for NPR


hide caption

toggle caption

Advertisement

Rich-Joseph Facun for NPR

LOGAN, Ohio – Before dawn, in a cold, blustery drizzle, a line forms outside a small, squat building on an open stretch of road on the outskirts of town.

“My heater quit working in my car,” Scott Skinner says good-naturedly to the next man in line. “Man, what kinda luck am I having.”

The building is called “The Market” because it has a food pantry, but Skinner and the others are here to sign up for heating assistance. He’s been calling for a month to get an appointment with no luck, so he showed up an hour ago to snag a walk-in slot.

Advertisement

The demand for help is more acute than usual because heating aid was suspended during the recent government shutdown. At the same time, SNAP food benefits were suspended for weeks, and some food pantry shoppers are still playing catch up.

One of those people is Lisa Murphy. She’s 61, disabled and relies on Social Security, and says it’s important to have “places like this that really help us.” 

“I still owe my gas bill. I owe $298,” Murphy says. “It’s hard to buy food and pay my bills, too.”

Lisa Murphy of Junction City, Ohio grocery shops at The Market at Hocking Drive on Dec. 9.

Lisa Murphy grocery shops at The Market food pantry in Logan, Ohio. She’s still behind on bills after SNAP food benefits were paused for two weeks during the recent federal shutdown.

Rich-Joseph Facun for NPR


hide caption

Advertisement

toggle caption

Rich-Joseph Facun for NPR

A detail from Miller's grocery cart; signs tell clients of the number of items that can be taken.

A detail from Miller’s grocery cart; signs tell clients the number of items that can be taken.

Rich-Joseph Facun for NPR

Advertisement


hide caption

toggle caption

Rich-Joseph Facun for NPR

Advertisement

But even as need grows with rising costs and unemployment, local anti-poverty groups like the one that runs The Market say their work has been threatened as never before amid the Trump administration’s funding cuts, pauses and reversals targeting a long list of safety-net programs. The shutdown was only the latest disruption that forced them to scramble to keep operating.

And, they say, the year of chaos has left deep uncertainty over which programs may be hit next.

‘Emergency response mode’

The Market in Logan, Ohio, is part of Hocking Athens Perry Community Action – HAPCAP for short – one of a thousand such agencies across the country that have been around since the 1960s. They connect some 15 million people with housing, health care, food aid and much more.

At HAPCAP, services include Meals on Wheels, Head Start, a public bus system, employment help, and a food bank that serves 10 counties across southeast Appalachian Ohio.

It’s an impressive range, but this year that’s also made it a big target for federal funding cuts. 

Advertisement

“Eighty percent of our funding comes from federal grants,” says executive director Kelly Hatas. The “worst day” of her career was back in January, when the Trump administration ordered a federal funding freeze, saying it wanted to shift priorities and promote efficiency.

“When we got that news we were in immediate emergency response mode, like, what are we going to do?” she says.

Kelly Hatas, executive director of Hocking Athens Perry Community Action, talks with Amyrose McManaway, 3, of Haydenville, Ohio, while her parents grocery shop at The Market at Hocking Drive on Dec. 9.

Kelly Hatas, executive director of Hocking Athens Perry Community Action (HAPCAP), talks with the child of a couple who are shopping at the food pantry. Hatas says the nonprofit has had to scramble all year as various safety-net programs were hit with federal funding cuts or pauses.

Rich-Joseph Facun for NPR/www.facun.com


hide caption

Advertisement

toggle caption

Rich-Joseph Facun for NPR/www.facun.com

The most urgent threat was to six Head Start centers.

“Our Head Start director was on a call with all of her center coordinators telling them we’re laying everyone off tomorrow,” Hatas recalls. “And then there was some secondary information that was like, ‘Just kidding … Head Start is excluded.’”

Advertisement

That whiplash shook people’s trust. And the hits kept coming.

In March, the administration canceled or paused a billion dollars that helped food banks. In May, President Trump’s budget called for zeroing out Head Start and heating assistance, along with major cuts to other safety-net programs like rental aid. He also proposed eliminating the $770 million dollar Community Services Block Grant that directly supports these anti-poverty groups, including it in a list of “woke programs.”

Congress eventually funded many of those programs, but the Office of Management and Budget took months to get out the block grant money. 

“OMB just decided not to spend it, totally usurping congressional authority,” says David Bradley, who advocates for these local groups with the National Community Action Foundation.

He says they’ve long had strong bipartisan support.

Advertisement

“So we’ve had two major fights with the administration,” he says. “We won them because Republicans helped.”

An overview of East Main Street in Logan, Ohio on Dec. 9.

East Main Street in Logan, a small town in southeast Appalachian Ohio.

Rich-Joseph Facun for NPR


hide caption

toggle caption

Advertisement

Rich-Joseph Facun for NPR

In a statement, an OMB spokesperson said these anti-poverty programs fund “radically partisan activities, like teaching toddlers to be antiracist and ‘LGBTQIA+ welcoming.’” It also criticized a program that combined affordable housing with clean energy “in the pursuit of both economic and environmental justice.”

“President Trump ran on fiscal responsibility and ending wasteful DEI spending in government,” the statement says.“The American taxpayer should not be made to fund critical race theory.”

Health and Human Services spokesman Andrew Nixon said the agency “administers CSBG consistent with the funding levels Congress provides to support services for low-income families.”

Advertisement

Funding chaos and uncertainty

In Ohio, Hatas says the state has shifted money to help address federal funding crises as they’ve popped up to keep programs going. But the biggest challenge remains uncertainty.

“The panic and the just day-to-day not knowing what’s going to happen, is just really difficult,” she says.

Because of that, HAPCAP has scaled back some plans, including for a new Head Start facility and a much-needed homeless shelter. It’s also had to pull out of food distribution at schools because of a lack of staff. Some employees are leaving, worried about losing their jobs. Others have been laid off or had their hours trimmed.

“It cut my paychecks completely in half,” says Kelsey Sexton, who manages the front desk but was shifted to part-time in the fall. “We have a mortgage, a car payment. With Christmas coming, my husband was like, what are we going to do?”

She was bumped back up to full-time – but so far only temporarily – after the shutdown pause in SNAP payments brought a surge of people to the food pantry.

Advertisement

Losing a job can be extra tough in rural communities.

“We don’t really have jobs growing on trees … and so there’s nowhere for these folks to go,” says Megan Riddlebarger, who heads the Corporation for Ohio Appalachian Development (COAD) half an hour away in Athens.

Hocking Athens Perry Community Action Administrative Clerk Kelsey Sexton; Executive Director of Corporation for Ohio Appalachian Development Megan Riddlebarger.

Kelsey Sexton (left) had her hours as a desk clerk at HAPCAP cut in half. Megan Riddlebarger (right) heads the Corporation for Ohio Appalachian Development and says anti-poverty agencies are important for local economies in this rural region.

Rich-Joseph Facun for NPR


hide caption

Advertisement

toggle caption

Rich-Joseph Facun for NPR

She oversees federal funding for 17 antipoverty groups across the eastern part of the state, and says they’re important for rural economies.

“These aren’t just, like, people volunteering for fun,” she says. “These are some of the biggest businesses in town, buying most of the products that are bought and sold in the town.”

Advertisement

Helping people stay warm and at home 

Down a flight of stairs from Riddlebarger’s office, five burly men at long desks take notes as Dave Freeman goes over how to properly install a water heater vent. It’s a refresher training class for inspectors, part of a weatherization assistance program the White House also wanted to end.

Freeman says many older homes in the area are full of cracks and crevices with almost no insulation.

“That house that you walk in (that) has the blanket at the stairway, so ‘Oh, honey, I haven’t been upstairs, it’s so cold up there,’” he says.

Weatherizing homes not only lets people live comfortably, it also saves them money.

“Say their electric bill goes down or gas bill goes down, they might be able to buy a pizza on a Saturday night,” Freeman says. “And that’s a big thing.”

Advertisement
Adam Murdock, left, attends attends a training class for weatherization inspectors at Corporation Ohio Appalachian Development's Weatherization Training Center as training coordinator Dave Freeman, right, gives instruction, on Dec. 9, in Athens, Ohio. COAD is a non-profit that provides essential services like weatherization, energy assistance, childcare resources, senior programs and workforce development.

Adam Murdock (left) attends attends a training class for weatherization inspectors at the Corporation for Ohio Appalachian Development.

Rich-Joseph Facun for NPR


hide caption

toggle caption

Rich-Joseph Facun for NPR

Advertisement

But COAD’s funding for weatherization was delayed months, which jeopardized staffing. “You can get paid to do similar work in the private sector, and so retaining that staff is already a challenge,” says Riddlebarger.

Most of the agencies she oversees were able to cover the gap until money finally came through in November. But she says it means squeezing what’s supposed to be a year-long program into about half that time “with the same expectations for performance reporting.”

Diana Eads’ volunteer job with COAD – which includes a small stipend – was also at risk earlier this year, when the Trump administration gutted AmeriCorps grants with little explanation. As part of the AmeriCorps Seniors companion program Eads visits and helps out low-income people.

“My companions have been elderly, they’re not able to get out,” she says. “They’re just one-step away from nursing home care.”

Advertisement
Diana Eads, 74, a volunteer for Corporation Ohio Appalachian Development, sits for her portrait at the COAD office on Dec. 9.

Diana Eads, 74, visits with elderly people as part of the AmeriCorps seniors program. When a funding cut threatened her small stipend for gas money, she told an 88-year-old woman who lives far away that she would keep visiting no matter what.

Rich-Joseph Facun for NPR


hide caption

toggle caption

Rich-Joseph Facun for NPR

Advertisement

If they were to land in a nursing home or assisted living, that could cost thousands of dollars a month in Medicaid spending. But Eads helps keep them at home for just $4 dollars an hour, to help cover gas or other small bills.

“Being rural, my one companion, it’s 56 miles roundtrip,” she says.

Riddlebarger managed to secure local philanthropic funding to keep operating, and after a legal challenge AmeriCorps federal funding was restored.

Through it all Eads reassured her companion, an 88-year old woman she’d been visiting for five years.

Advertisement

“I told her no matter what happened, I would not stop visiting,” Eads says. “That was important.”

A grim 2026 outlook

After a year struggling to keep serving those most in need, advocates say they don’t see much relief in site. Republicans in Congress passed major cuts to Medicaid and SNAP food aid and those will start to take hold.

The Trump administration also is considering dramatic limits to rental assistance and has laid out major cuts to long-term housing for people leaving homelessness, a move that faces a legal challenge.

On top of that, the administration’s mass firings and buyouts hit hard in offices that administer various safety-net programs.

Anthony Waddell of Haydenville, Ohio enters the The Market at Hocking Drive on Dec. 9.

The Market runs a food pantry and helps connect people with other services. In December, people seeking an appointment for heating assistance often line up outside before dawn.

Rich-Joseph Facun for NPR

Advertisement


hide caption

toggle caption

Rich-Joseph Facun for NPR

Advertisement

Riddlebarger says most anti-poverty funding already falls far short of the need, and making it even harder to help people is exhausting.

“Not knowing which of our many services we are going to be able to keep operating makes us waste valuable capacity trying to plug holes that shouldn’t be holes,” she says. “We’re just breaking the wheel and reinventing it at a great cost to all parties.”

Continue Reading

News

‘Bomb cyclone’ forecasted to bring heavy snow, blizzard conditions and dangerous travel

Published

on

‘Bomb cyclone’ forecasted to bring heavy snow, blizzard conditions and dangerous travel

People walk through the snow in Brooklyn after an overnight storm on Saturday in New York City.

Spencer Platt/Getty Images


hide caption

toggle caption

Advertisement

Spencer Platt/Getty Images

An intense cyclone system is fueling a mix of severe weather, including a winter storm that will impact upper parts of the United States.

Heavy snow, blizzards, extreme cold and damaging winds are likely to create hazardous conditions stretching from Montana east to Maine, and Texas north to Pennsylvania, according to the National Weather Service (NWS).

More than eight million people were under winter storm warnings from the NWS on Sunday afternoon. Nearly two million people were under blizzard warnings. Meteorologists warn that after winter weather Friday and Saturday, an arctic front clashing with warm air could rapidly intensify into a ‘bomb cyclone’ over the Midwest and Great Lakes through Monday. A ‘bomb cyclone’ or bombogenesis is a rapidly deepening area of low pressure that creates harsh weather conditions.

Advertisement

“We are anticipating some pretty big snows over the next 24 hours, especially across east central Minnesota to northern Wisconsin to the Upper Peninsula of Michigan. A lot of those places will have 6-12 inches,” NWS Lead Forecaster Bob Oravec told NPR on Sunday.

Blizzard conditions will cause near zero visibility and possible power outages Sunday night though Monday evening in some locations in Michigan’s Upper Peninsula, according to the NWS Marquette. A foot of snow or more is possible in areas along Lake Superior with 40 to 65 mile per hour winds, according to forecasts.

Marquette Mayor Paul Schloegel told NPR on Sunday the Marquette Board of Light & Power is prepared to handle any loss of electricity. He said in an email the main priority is keeping people safe.

“We tend to heed the advice of our weather forecasters and prepare to hunker down as needed,” Schloegel wrote. “As far as taking care of the snow, our extremely dedicated public works and MDOT crews do a great job taking care of our residents, they are true professionals. Roads are usually back to normal within 24 [hours].”

Schloegel said Marquette residents appreciate a good blizzard while taking precautions.

Advertisement

“We choose to live here for our love of [four] full seasons and appreciate the effect the greatest lake, Lake Superior, has on our climate,” he said.

Minnesota is also bracing for major impacts. Blizzard and winter storm warnings and advisories are in place for most of the state. As much as 10 inches of snow could fall in the Twin Cities and potentially life-threatening travel conditions are likely through early Monday morning, according to the NWS.

The ‘bomb cyclone’ is also sending cold temperatures below freezing.

Residents of Havre, Mont., about 45 miles south of the Canadian border, could feel wind chill values as low as 15 degrees below zero late Sunday. The actual temperature is forecast to fall to 2 degrees below zero.

Farther south in Dallas, Texas, temperatures are expected to drop dramatically from the 80s on Sunday to highs in the 40s on Monday, according to the NWS.

Advertisement

In the Northeast, freezing rain could cause travel problems, including icing in northern New England and northern New York state, late Sunday into Monday, according to Oravec.

When colder air moves into New York City early this week, remaining snow on the ground from the weekend storm will freeze and create further hazardous travel conditions, Oravec said.

Continue Reading

Trending